Scientists have shown that TGFβ1 inhibits DNMT1 and DNMT3β in hepatocellular carcinoma, which led to overexpression of CD133 in the cells by demethylation of CD133 promoter-1. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.